BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 15864213)

  • 1. [Oxaliplatin neurotoxicity: a report of three cases with post-operative exacerbation].
    Cournede A; Ries P; Richard K; Guillain A; Dahan L; Grandval P; Pourroy B; Moutardier V; Hardwigsen J; Braguer D; Seitz JF
    Gastroenterol Clin Biol; 2005 Apr; 29(4):461-4. PubMed ID: 15864213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exacerbation of oxaliplatin neurosensory toxicity following surgery.
    Gornet JM; Savier E; Lokiec F; Cvitkovic E; Misset JL; Goldwasser F
    Ann Oncol; 2002 Aug; 13(8):1315-8. PubMed ID: 12181257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies.
    Culy CR; Clemett D; Wiseman LR
    Drugs; 2000 Oct; 60(4):895-924. PubMed ID: 11085200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.
    Rubbia-Brandt L; Audard V; Sartoretti P; Roth AD; Brezault C; Le Charpentier M; Dousset B; Morel P; Soubrane O; Chaussade S; Mentha G; Terris B
    Ann Oncol; 2004 Mar; 15(3):460-6. PubMed ID: 14998849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 1 study on S-1 and oxaliplatin therapy as an adjuvant after hepatectomy for colorectal liver metastases.
    Takahashi M; Hasegawa K; Oba M; Saiura A; Arita J; Sakamoto Y; Shinozaki E; Mizunuma N; Matsuyama Y; Kokudo N
    Invest New Drugs; 2016 Aug; 34(4):468-73. PubMed ID: 27155613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant treatment with weekly high-dose 5-fluorouracil as a 24h-infusion, folinic acid and biweekly oxaliplatin in patients with primary resectable liver metastases of colorectal cancer: long-term results of a phase II trial.
    Boxberger F; Albrecht H; Konturek PC; Reulbach U; Maennlein G; Meyer T; Hohenberger W; Hahn EG; Wein A
    Med Sci Monit; 2010 Feb; 16(2):CR49-55. PubMed ID: 20110914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sinusoidal obstruction syndrome after oxaliplatin-based chemotherapy.
    Seo AN; Kim H
    Clin Mol Hepatol; 2014 Mar; 20(1):81-4. PubMed ID: 24757663
    [No Abstract]   [Full Text] [Related]  

  • 8. Reduction of nonresectable liver metastasis from colorectal cancer after oxaliplatin chemotherapy.
    Bismuth H; Adam R
    Semin Oncol; 1998 Apr; 25(2 Suppl 5):40-6. PubMed ID: 9609107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting high grade lesions of sinusoidal obstruction syndrome related to oxaliplatin-based chemotherapy for colorectal liver metastases: correlation with post-hepatectomy outcome.
    Soubrane O; Brouquet A; Zalinski S; Terris B; Brézault C; Mallet V; Goldwasser F; Scatton O
    Ann Surg; 2010 Mar; 251(3):454-60. PubMed ID: 20160638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxaliplatin hepatic arterial infusion chemotherapy for hepatic metastases from colorectal cancer: a phase I-II clinical study.
    Fiorentini G; Rossi S; Dentico P; Meucci F; Bonechi F; Bernardeschi P; Cantore M; Guadagni S; De Simone M
    Anticancer Res; 2004; 24(3b):2093-6. PubMed ID: 15274406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nodular regenerative hyperplasia (NRH) complicating oxaliplatin chemotherapy in patients undergoing resection of colorectal liver metastases.
    Morris-Stiff G; White AD; Gomez D; Cameron IC; Farid S; Toogood GJ; Lodge JP; Prasad KR
    Eur J Surg Oncol; 2014 Aug; 40(8):1016-20. PubMed ID: 24370284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis.
    Ji JH; Park SH; Lee J; Kim TW; Hong YS; Kim KP; Kim SY; Baek JY; Kang HJ; Shin SJ; Shim BY; Park YS
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):223-30. PubMed ID: 23689915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A case of hypersensitivity reaction to reintroduced-oxaliplatin at the second course of oxaliplatin-based chemotherapy after neoadjuvant chemotherapy for liver metastases from colon cancer].
    Katayose Y; Nakagawa K; Onogawa T; Yoshida H; Motoi F; Naitoh T; Rikiyama T; Egawa S; Unno M
    Gan To Kagaku Ryoho; 2011 Dec; 38(13):2651-3. PubMed ID: 22189236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxaliplatin-based chemotherapy in the treatment of elderly patients with metastatic colorectal cancer (CRC).
    Berretta M; Zanet E; Nasti G; Lleshi A; Frustaci S; Fiorica F; Bearz A; Talamini R; Lestuzzi C; Lazzarini R; Fisichella R; Cannizzaro R; Iaffaioli RV; Berretta S; Tirelli U
    Arch Gerontol Geriatr; 2012; 55(2):271-5. PubMed ID: 21937127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of postoperative oxaliplatin- or irinotecan-based chemotherapy after curative resection of synchronous liver metastases from colorectal cancer.
    Hsu HC; Chou WC; Shen WC; Wu CE; Chen JS; Liau CT; Lin YC; Yang TS
    Anticancer Res; 2013 Aug; 33(8):3317-25. PubMed ID: 23898098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severe anaphylactic reactions in patients receiving oxaliplatin therapy: a rare but potentially fatal complication.
    Lee MY; Yang MH; Liu JH; Yen CC; Lin PC; Teng HW; Wang WS; Chiou TJ; Chen PM
    Support Care Cancer; 2007 Jan; 15(1):89-93. PubMed ID: 16865410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.
    Tsuruta A; Yamashita K; Tanioka H; Tsuji A; Inukai M; Yamakawa T; Yamatsuji T; Yoshimitsu M; Toyota K; Yamano T; Nagasaka T; Okajima M
    Drug Des Devel Ther; 2016; 10():3827-3835. PubMed ID: 27920498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I-II study.
    Seium Y; Stupp R; Ruhstaller T; Gervaz P; Mentha G; Philippe M; Allal A; Trembleau C; Bauer J; Morant R; Roth AD
    Ann Oncol; 2005 May; 16(5):762-6. PubMed ID: 15817597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatic veno-occlusive disease after neoadjuvant treatment of colorectal liver metastases with oxaliplatin: a lesson of the month.
    Schouten van der Velden AP; Punt CJ; Van Krieken JH; Derleyn VA; Ruers TJ
    Eur J Surg Oncol; 2008 Mar; 34(3):353-5. PubMed ID: 17207961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer.
    Leonard GD; Wright MA; Quinn MG; Fioravanti S; Harold N; Schuler B; Thomas RR; Grem JL
    BMC Cancer; 2005 Sep; 5():116. PubMed ID: 16168057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.